Trial Profile
PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN'S LYMPHOMA
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 31 Jul 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2019.
- 13 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.